Why Genetic Testing Comes Up in Breast Cancer Care
Genetic testing for breast cancer looks for inherited changes (variants) in your DNA that raise the chance of developing breast and other cancers. It is most often discussed after a personal or family history that suggests higher risk, or as part of routine care for certain groups. Results can change how aggressively your team screens, whether they recommend risk-reducing surgery or medication, and whether relatives should consider testing. This explainer focuses on purpose, limits, and practical next steps rather than individual medical advice.
What Is Hereditary Cancer and Why It Matters
Hereditary cancer syndromes are passed from parent to child in families. The best-known breast cancer genes are BRCA1 and BRCA2, but many other genes, such as TP53, PTEN, CDH1, PALB2, ATM, and CHEK2, also affect risk. Inherited variants in these genes can increase lifetime risks of breast, ovarian, prostate, and other cancers. Understanding whether a gene change is present helps clinicians tailor prevention, screening, and treatment strategies over the long term.
How Inherited Risk Differs From Other Risk Factors
Most breast cancers are not inherited. Risk from an inherited variant is typically higher than average but does not guarantee that cancer will develop. Other factors, such as age at first period, age at menopause, hormone use, childbearing history, alcohol intake, and weight, also contribute. Genetic risk is one piece of a larger puzzle that clinicians use to estimate overall risk and decide on follow-up.
How Genetic Testing Is Done
Testing is usually done with a blood or saliva sample sent to a certified laboratory. A tumor biopsy can be used when blood is unavailable. Modern panels often examine many genes at once (multigene or panel testing), rather than only BRCA1/2. A genetic counselor or physician helps decide which test is appropriate, explains what results could mean, and supports decision-making before and after results return.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Sample Type | Blood or saliva; tumor biopsy if blood unavailable | Clinical guidelines |
| Typical Turnaround | 2–6 weeks, depending on test complexity | Laboratory estimates |
| Pre-Test Counseling | Discussion of benefits, limits, and possible outcomes | Best practice standards |
| Post-Test Counseling | Result interpretation and next-step planning | Best practice standards |
| Laboratory Accreditation | CLIA/CAP certification required in the U.S. | Regulatory requirements |
Understanding the Results
Labs classify variants as benign, likely benign, uncertain significance, likely pathogenic, or pathogenic. A pathogenic or likely pathogenic result in a breast cancer gene usually means higher lifetime cancer risk and can affect relatives. A benign or likely benign result generally indicates no increased risk from that variant. Results classified as uncertain significance may need more investigation or periodic reclassification as evidence evolves.
Positive, Negative, and Uncertain Results at a Glance
- Pathogenic/Likely Pathogenic: Higher estimated risk; may prompt enhanced screening, risk-reducing options, and relative testing.
- Benign/Likely Benign: No increased risk from this variant; routine screening may be appropriate based on other factors.
- Variant of Uncertain Significance: Clinical significance unclear; reclassification and additional research may be needed over time.
How Results Can Change Screening and Prevention
When a pathogenic or likely pathogenic result is found, clinicians may suggest earlier or more frequent mammograms and MRIs, or recommend discussions about risk-reducing medications or surgery. Decisions depend on the specific gene, estimated risk, age, childbearing plans, overall health, and personal preferences. Even with an elevated genetic risk, choices are individualized and may evolve with new evidence and life circumstances.
Examples of Guideline-Directed Options
| Risk Scenario | Potential Action | Goal |
|---|---|---|
| High genetic risk, average population risk | Enhanced screening (earlier/more frequent mammograms or MRI) | Earlier detection |
| Very high genetic risk (e.g., BRCA) | Risk-reducing medications or preventive surgery | Lower chance of developing cancer |
| Uncertain significance or low-level variant | Clinical evaluation and possible follow-up testing | Clarify risk and guide decisions |
Who Should Consider Testing and When
Guidelines often suggest genetic testing for breast cancer when there is a personal or family history that meets certain patterns, such as early-onset breast cancer, multiple relatives with breast or ovarian cancer, male breast cancer, or known family mutations. People with Ashkenazi Jewish ancestry and certain other patterns may also be candidates. A healthcare provider or genetic counselor can assess whether testing is appropriate now or whether timing or scope should change.
Testing Pathway at a Glance
- Assessment of personal and family history by a clinician or counselor.
- Selection of an appropriate test based on indicated genes.
- Pretest counseling to review potential outcomes and implications.
- Laboratory analysis and result reporting.
- Posttest counseling to interpret results and plan next steps.
Limitations, Risks, and Realistic Expectations
Testing cannot predict exactly when or whether cancer will occur, only that risk is higher than average. Not all high-risk people will develop cancer, and some with lower-risk results may still benefit from tailored strategies. Emotional impact, privacy concerns, and implications for relatives are important to discuss. Health insurance and workplace protections vary by region; clinicians can help navigate these issues and connect people with resources.
Bottom Line
Genetic testing for breast cancer is a powerful tool for understanding inherited risk and shaping prevention and screening plans, but it is one part of a broader approach that includes family history, lifestyle factors, and clinical judgment. Careful pre- and post-test counseling, clear communication within your care team, and regular follow-up are central to using results effectively over the long term.